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A B S T R A C T
Introduction: Colorectal cancer (CRC) is one of the most cancer-related mortalities worldwide and
remains a major public health issue. Despite several attempts to develop promising therapies for CRC, its
survival rate decreases with metastasis. Cyclin-dependent kinases (CDKs) are a family of protein kinases
with various regulatory activities including cell cycle, mRNA expression, transcription, and differentia-
tion. Aside from their role in cell proliferation when mutated, abnormal expression of these genes has
been reported in some human cancer subtypes. This study explored the roles and therapeutic potentials
of CDK 1 and 4 as prognostic biomarkers in CRC.
Methods: Bioinformatics analyses were carried out to demonstrate the expression and prognostic values
of CDK-1 and CDK-4 with immune infiltrate in CRC.
Discussion: CDK levels in CRC were remarkably higher than those in normal tissues (p < 0.05), and
overexpression in CRC tissues was significantly related to nodal metastatic status (p < 0.05) and histological
subtypes. Kaplan-Meier analyses showed that patients with CRC who exhibited CDK-1 overexpression had
worse overall survival (OS) as against patients with CDK-4 overexpression. The alteration observed was a
mutation while the mutation hotspots include E163* and R24A/C/H/L respectively for CDK-1 and CDK-4 on
the Pkinase domain. Of the associated genes, AURKA and RB1 were predominantly altered. Furthermore,
CDK-4 is positively correlated with tumor purity in both COAD and READ while CDK-1is only positively
correlated in COAD. CDK-1 overexpression was significantly associated with poor prognosis as opposed to
CDK-4.
Conclusion: The expression and prognostic values of AURKA and RB1 may also be significant to CRC
diagnosis. CDKs together with the co-expressed genes and their association with immune infiltrates may
serve as target molecules for immunotherapy in CRC.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Colorectal carcinogenesis is a sequential process that results
from genetic alterations in either oncogenes or tumor-suppressor
genes. Molecular alterations of genes have also been implicated in
the development and prognosis of CRC. The survival rate of CRC
patients relies on the stage during diagnosis and decreases as the
tumor advances [1]. To date, the mechanisms that drive the
pathogenesis of CRC are poorly understood and the development of
resistance to cytotoxic and targeted therapies remains the primary
reason for treatment failure. Therefore, the development of new
therapeutic targets that can translate into better clinical outcomes
is urgently required for individuals with CRC. Additionally, the
identification of biomarkers for early diagnosis and prognosis
could improve the efficiency of current treatments for CRC and
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unctions in cancer have been comprehensively investigated; they
re involved in regulation of the cell cycle by interacting with
pecific cell-cycle–regulatory cyclins [3]. The CDK family consists
f 20 members (CDK-1 to CDK-20). This class of serine/threonine
inases has been classified into two groups based on their
nvolvement in tumor formation through the regulation of cell-
ycle or transcription [4–6]. CDK-1, CDK-4, and CDK-5 fall within
he cell-cycle-related subfamilies while CDK-7, CDK-8, CDK-9, CDK-
1, and CDK-20 are classified as transcriptional subfamilies.
alumbres and Barbacid [7] reported that mammalian cells
equire a step-wise activation of at least four different CDKs to
rive cells through interphase, and for CDK-1 to proceed through
itosis. CDK-1 promotes the G2–M transition and regulates G1
rogression and G1–S transition [8,9], suggesting that CDK-1 is one
f the most important CDKs for cell-cycle regulation [10].
ncontrollable cell proliferation is one of the hallmarks of
alignant tumors and is often driven by mutations in CDK
ctivity. Altered CDK expression and/or activity is observed in
any cancer subtypes [11,12]. In addition to cell-cycle regulation,
DK-1 may regulate apoptosis by inhibiting phosphorylation of
aspase-8 [13,14]. CDK-1 functions include apoptosis, senescence,
ngiogenesis, cell cycle progression, and adhesion/migration [15–
7], all of which are believed to contribute to its role in
umorigenesis. CDK-1 has been implicated in several cancers,
ncluding ovarian [18,19], thyroid [20], bladder [21], colorectum
22], breast [23,24], and liver cancer [25]. CDK-4 is also a key player
n cell cycle and mediates cell progression through the G1 phase
26]. Its dysregulation has been found to play a significant role as
egulator of signaling in cellular pathways in several diseases.
ince the frequent deregulation of CDK-4 in cancer often leads to
ddiction to its activity, it is emerging as a bright therapeutic target
27,28]. CDK inhibitors were recently investigated in preclinical
nd clinical trials. These inhibitors are believed to act as anti-
ancer drugs by blocking CDKs to prevent uncontrolled cellular
roliferation that is a hallmark of cancers specifically in CRC [29].
n earlier studies, the relationship between genetic mutations and
DK overexpression were investigated [30]. The overexpression of
DK4 was observed in colorectal tumors that carry the type II
ransforming growth factor-β receptor mutation [31]. This muta-
ion resulted in microsatellite instability in 15 % CRC patients [31].
hao et al. [32] reported the expression of CDK-4 in 74 specimens
through grading, and concluded that stronger immunostaining for
CDK-4 was predictive of a worse prognosis (P < 0.001). Tumor
immune cells play essential roles in cancer development and
progression. However, the association with prognosis in CRC
remains elusive [33]. A recent study showed that the expression of
CDK-9 was negatively associated with the infiltration of CD8+ T
cells at the tumor site in CRC patients [34]. Thus, CDKs may have
roles in tumorigenesis, progression, and metastasis, and may serve
as an underlying prognostic factor for tumors. Since the TCGA
transcriptomic datasets have proven the relevance of CDKs in CRC
[35], targeting CDKs could prove an effective strategy to enhance
the efficacy of treatment in CRC. With clear emphasis on CDK-1 and
CDK-4, the association between CDKs expression and clinical
pathological parameters, including prognostic value, was investi-
gated, and the biological function and immune infiltrate activities
of CDKs in patients with CRC was examined using an in silico
approach (Fig. 1). This study suggests that the involvement of CDKs
in CRC has a pivotal clinical significance in CRC.
2. Materials and methods
2.1. mRNA expression analysis
The web-based Oncomine database accessed at https://www.
oncomine.org/resource/login.html, was used to investigate the
transcription levels of CDK-1 and CDK-4 in CRC using the following
parameters: p<1  10-4, fold-change >2 and gene ranking in the
top 10 %. The mRNA expressions were compared between normal
and tumor clinical samples.
2.2. Prognostic analysis
The correlation between CDK-1 expression and survival in CRC
was analyzed by PrognoScan database (http://www.abren.net/
PrognoScan/), Gene Expression Profiling Interactive Analysis
(GEPIA) (http://gepia.cancer-pku.cn/index.html) and UCSC-Xena
(https://xena.ucsc.edu/kaplan-survival-analysis/). Xena analyzes
cancer genomics and its associated clinical data. The threshold
was adjusted to cox p-value < 0.05. The PrognoScan database was
used to validate the prognostic value of CDK-1 and CDK-4
expression in patients with CRC. The adjusted p-value threshold
was <0.05.Fig. 1. Schematic representation of the workflow.
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UALCAN is a comprehensive, user-friendly, and interactive web
resource for analyzing cancer OMICS data [36]. The correlation
between CDKs expression and lymph node metastasis in colon and
rectum adenocarcinomas was analyzed using UALCAN (http://
ualcan.path.uab.edu/). CDK-1 expression and the clinicopatholog-
ical parameters relationship was provided in a tabular form.
2.4. Predicted protein interaction
Co-expressed proteins were identified according to a method
previously described by Fadaka et al. [37]. The database was
accessed, downloaded and installed from http://www.cytoscape.
org/ (v3.7.2) along with the STRING plug-in (http://string-db.org/
v11). Only genes with a 0.90 confidence level as the minimum
required interaction score were considered.
2.5. Gene ontology
FunRich is a stand-alone software tool used mainly for
functional enrichment and interaction network analysis of genes
and proteins [38]. The enrichment analyses of gene ontology such
as cellular component (CC), biological processes (BP), molecular
function (MF) and biological pathway were analyzed using the
functional enrichment (v3.1.3) software accessed at http://funrich.
org/index.html.
2.6. Mutations analysis for CDK-1 and CDK-4
The Catalogue of Somatic Mutations in Cancer (COSMIC)
database coupled with cBioPortal was used to detect genetic
mutation frequencies and hotspots for CDK-1 and CDK-4. The
COSMIC v90, (released 05-SEP-19) database accessed at https://
cancer.sanger.ac.uk/cosmic is a comprehensive resource for
exploring the effect of somatic mutations in all human cancer
subtypes [39,40]. This database also provides information
pictorially on the distribution and substitutions on the coding
strand in cancer subtypes.
2.7. Genomic analysis of CDK-1 and CDK-4
Cancer genomics analysis was performed using the cBioPortal
database for Cancer Genomics (http://www.cbioportal.org/). This
tool was used to investigate the genes positively associated with
CDK-1 and CDK-4 expression in CRC and the RNA sequencing data
and copy number variance. cBioPortal was also used to analyze the
alteration frequency of CDK-1 and CDK-4 mutations in CRC. The ten
combined studies used are listed as follows: Colon Cancer (CPTAC-
2 Prospective, Cell 2019) [41]; Colorectal Adenocarcinoma (TCGA
PanCancer Atlas) [42]; Colorectal Adenocarcinoma (TCGA
Firehose Legacy); Colorectal Adenocarcinoma (TCGA, Nature
2012) [43]; Colorectal Adenocarcinoma (Genentech, Nature
2012) [44]; Colorectal Adenocarcinoma (DFCI, Cell Reports 2016)
[45]; Metastatic Colorectal Cancer (MSKCC, Cancer Cell 2018) [46];
Rectal Cancer (MSK Nature Medicine 2019); Colon Adenocarcino-
ma (CaseCCC, PNAS 2015) [47]; Colon Adenocarcinoma Triplets
(MSKCC, Genome Biol 2014) [48].
2.8. Immune Cells Tumor-Infiltration analysis
interactions in CRC. Six immune infiltrates namely; B cells, CD4+ T
cells, CD8+ T cells, Neutrophils, Macrophages and Dendritic cells
were analyzed using this algorithm. Furthermore, the expression
report of Oncomine was validated by TIMER v2.0.
2.9. Statistical analysis
Based on the Bioinformatics approaches employed, the Kaplan-
Meier plot was generated by PrognoScan, GEPIA, and UCSC-Xena.
PrognoScan and GEPIA analyses were displayed along with
Hazzard ratio (HR) and p-values of the log-rank test. Expression
analysis results were presented as fold changes, p-values,
and ranks. The difference in expression was verified using
Student’s t-test. Differences between and within groups were
carried out using ANOVA for multiple tissues. The correlation of
gene expression was assessed by statistical significance, Pearson's
correlation, and spearman’s correlation. The scatter/ boxplot was
created using TIMER computational tool and was calculated using
spearman’s correlation between two groups of genes of interest.
The significance level was set as p < 0.05.
3. Results
3.1. Expression of CDKs
To determine the expression of CDKs among subtypes of CRC, it
is important to explore their expression among different cancer
types (Figs. 2a, b and 3 ). The expression of these genes was
investigated in both solid tumors as well as hematological
malignancies (Fig. 2). The expression of CDK-1 was upregulated
in 17 cancers including breast cancer, CRC, lung cancer and
sarcoma in total unique analyses of 455 different datasets.
Underexpression of this gene was also identified in brain and
central nervous system (CNS) cancer, breast cancer and leukemia.
Although the expression of CDK-4 was determined in 463 different
analyses, its expression was up-regulated in 53 cancer datasets and
downregulated in two cancer studies (leukemia). The pathogenesis
of CRC is unique among human tumors. This common malignant
tumor usually develops in a benign precursor lesion, the adenoma,
which is visible on the mucosal surface of the large bowel,
constituting an adenoma-adenocarcinoma sequence. The expres-
sion of CDK-1 and CDK-4 were significantly elevated in multiple
CRC types when compared to normal colorectum tissues (p = 1.0 
104). These CRC types include Colon Adenocarcinoma, Cecum
Adenocarcinoma, Cecum Adenocarcinoma, Rectosigmoid Adeno-
carcinoma, Colon Mucinous Adenocarcinoma, Rectal Mucinous
Adenocarcinoma, Rectal Adenocarcinoma, Colon Adenocarcinoma,
Colon Adenoma, Rectum Adenoma, Colon Adenocarcinoma, Rectal
Adenocarcinoma, Colorectal Carcinoma and Colorectal Adenocar-
cinoma with different p-values and fold changes (Table 1 and
Fig. 5).
These expressions were further validated using the computa-
tional tool (TIMER v 2.0) (Fig. 2b). Clear emphasis were placed on
CRC as the cancer type of interest and their expressions were
evaluated using the GEPIA database (Fig. 3b).
3.2. Genetic alterations of CDKs and clinicopathological parameters in
CRC patients
To understand the importance and mechanism underlying theTumor Immune Estimation Resource (TIMER v 2.0), a web-
based database for comprehensive analysis of tumor-infiltrating
immune cells [49,50] (https://cistrome.shinyapps.io/timer/) was
used to assessed the interactions between the genes of interest and
the immune system for better understanding of CDKs-immune3
expression of CDKs in CRC, the expression profiles of CDKs were
examined across CRC subtypes using OMICS data (obtained from
the UALCAN database) based on different clinical-pathological
parameters (Table 2). This analysis differs from Oncomine
expression analysis in Table 1 which evaluated the expression of
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athological parameters. Based on gender, an increase in CDK
xpression was observed in males and females with CRC when
ompared to individuals without the disease. The age criterion
emonstrated significantly increased expression of CDK genes.
RNA levels in tumors of patients of all ages >20 - 100 years,
adenocarcinoma (COAD) and Rectum adenocarcinoma (READ)
(Fig. 4).
3.3. Survival analysis
The prognostic values of CDK-1 and CDK-4 were assessed using
ig. 3. Anatomy of the colorectum and expression signature of CDK-1 and CDK-4 in colon (COAD) and rectum (READ) adenocarcinomas. The different sections (labeled) of the
olorectum (A) can be affected by CRC. Expression signatures of CDK-1 and CDK-4 in COAD and READ was analyzed using the GEPIA database (B).
ig. 2. mRNA expression of CDK-1 and CDK-4 in various cancer types. The mRNA expression of CDK-1 and CDK-4 (cancer against normal tissue) was evaluated using the
ncomine (A) and TIMER (B) computational tools. The red color represents significant overexpression whereas blue color represents reduced expression. The green box
ighlights the cancer of interest, *p < 0.05, **p < 0.01 and ***p < 0.001.ompared with normal individuals of all ages. In addition, the CDKs
RNA expression was significantly increased in sample types (p <
.0  1012), race, weight, tumor stages, histological subtypes, and
odal metastasis status compared with the corresponding normal
issues (Table 2). The nodal metastatic status of these genes was
epresented with a box plot using the CRC subtypes Colon4
the PrognoScan-based Kaplan-Meier analyses. The overall survival
(OS) and disease-free survival (DFS) of CDK-1 were determined in
five different datasets (p < 0.05) in CRC. The results obtained were
consistent across the five datasets and confirmed that the
expression of CDK-1 positively correlated with poor OS rates in
CRC patients (Fig. 6). In contrast, when the prognostic value of
A.O. Fadaka, N.R. Samantha Sibuyi, O.O. Bakare et al. Biotechnology Reports 29 (2021) e00602CDK-4 was assessed in three different databases using the same
bioinformatics tools (Fig. 7B-D), the expression of CDK-4 in the
GSE14333 dataset inversely correlated to poor prognosis in
disease-free survival (DFS) in CRC (Fig. 7). Although CDK-1 and
CDK-4 were positively correlated, their prognostic values with
respect to mRNA expression are different (Fig. 7A and Supplemen-
tary Fig. 1).
entries, experimental validation, text mining, co-expression and/or
protein homology (Fig. 8).
3.5. Gene ontology of associated genes
To identify functional categories and characteristic biological
attributes of CDKs (Fig. 8), Gene Oncology (GO) enrichment
analysis was performed using the FunRich software.
Table 1
CDK-1 mRNA expression in CRC compared to normal tissues (Oncomine).
CRC Subtype Fold-change P-value Rank (%) Sample Source
Colon Adenocarcinoma 2.025 3.73  106 1 62 [51]
Cecum Adenocarcinoma 3.437 6.72  1019 1 237 TCGA, 2011
Rectosigmoid Adenocarcinoma 2.059 6.07  1010 1 237 TCGA, 2011
Colon Mucinous Adenocarcinoma 3.249 8.81  1014 1 237 TCGA, 2011
Rectal Mucinous Adenocarcinoma 3.348 8.89  107 1 237 TCGA Colorectal, 2011
Rectal Adenocarcinoma 3.181 4.15  1019 3 237 TCGA Colorectal, 2011
Colon Adenocarcinoma 3.374 3.27  1018 4 237 TCGA Colorectal, 2011
Colon Adenoma 2.618 4.10  1019 1 64 [52]
Rectum Adenoma 3.027 4.93  107 3 64 [52]
Colon Adenocarcinoma 2.730 1.05 105 2 36 [53]
Rectal Adenocarcinoma 2.535 1.25  1035 1 130 [54]
Colorectal Carcinoma 2.447 4.31  1012 1 105 [55]
Colorectal Adenocarcinoma 2.060 1.98  1010 4 105 [55]
Colorectal Carcinoma 3.636 8.57  1011 4 82 [56]
Note: Adenoma is a benign for of adenocarcinoma. Sometimes this counterpart transforms into adenocarcinomas.
Table 2
Clinico-pathological parameters of CRC patients and CDK-1 and CDK-4 mRNA expression.
Parameter Characteristics Number of cases CDKs mRNA CDK-1 p-value CDK-4 p-value
Gender Normal (male & female) 41 –
Male 156 " 1.62  1012* 1.45  1015*
Female 127 " 1.00  1012* 1.30  1011*
Age Normal 41 –
2140yrs 12 " 1.55  1006* 1.11  1007*
4160yrs 90 " 1.00  1012* 1.00  1002*
6180yrs 149 " 1.00  1012* 1.60  1005*
81100yrs 32 " 1.11  1016* 1.91  1007*
Sample types Normal 41 –
Primary tumor 286 " 1.00  1012* 1.55  1006*
Race Normal 41 –
Caucasian 195 " 1.00  1012* 3.10  1011*
African American 55 " 1.62  1012* 2.32  1012*
Asian 11 " 8.33  1005* 3.44  1005*
Weight Normal weight 41 –
Extreme weight 70 " 1.62  1012* 2.42  1014*
Obese 74 " 1.62  1012* 3.62  1014*
Extreme obese 56 " 1.00  1012* 4.00  1015*
10 " 1.02  1004* 2.02  1014*
Stages Normal I 41 –
II 45 " 1.00  1012* 1.11  1015*
III 110 " 1.63  1012*a 5.73  1016*a
IV 80 " 1.625  1012*a 2.65  1002*a
39 " 1.00  1012* 2.00  1011*
Histological subtype Normal Adenocarcinoma 41 –
Mucinous 234 " 1.63  1012 a* 2.63  1001 a*
Adenocarcinoma 37 " 4.80  1011 a* 2.80  1012 a*
Nodal metastasis status Normal N0 41 –
N1 166 " 1.00  1012*a 1.00  1012*a
N2 70 " 1.00  1012*ab 1.00  1012*ab
47 " 1.00  1012*b 1.00  1012*b
Note: -, normal expression; ", overexpression of both CDK-1 and CDK-4; non-cancer, normal people with no CRC within the set parameters.3.4. Protein partners of CDKs
Using CDK-1 and CDK-4 as a queries, associated proteins were
generated using STRING v11 plugin Cytoscape 3.7.2with a 0.90
confidence level as the minimum required interaction. Each of
these genes generated 10 other genes through curated database5
Analysis of GO terms were filtered for cellular component (CC),
biological process (BP), molecular function (MF) and biological
pathway (BP) (Fig. 9). The top 10 GO terms of the associated genes
in BP, CC, MF and BP were considered significant at p-value of <
0.05 (Fig. 9A-D). These genes were involved in the different GO
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omplex, ontology; CC and cell cycle, ontology; BP. The biological
athway analysis showed that cell cycle was highly enriched
mongst the CDKs associated genes, which are closely related to
OXM1 transcription factor network, regulation of retinoblastoma
rotein and the E2F transcription factor network (Fig. 9D).
.6. Genomic correlation of CDK genes in clinical data
To lower the barriers of access to the complex data sets and
ccelerate the translation of genomic data into new biological
nsights, therapies, and clinical trials, the cBioPortal database was
sed to profile the CDK genes in ten CRC studies. This software tool
ccessed at https://www.cbioportal.org/ reduces molecular profil-
ng data from cancer tissues and cell lines into readily under-
tandable genetic, epigenetic, gene expression and proteomic
vents. The patterns of gene alterations were visualized in specific
RC studies and all the relevant genomic alterations in these
tudies were reported (Figs. 10 and 11, Tables 3 and 4). The results
re represented as a bar graph plot of alteration frequency (%)
gainst mutation data, copy number alteration and study data
Fig. 10). The mutation observed after the query of the CDKs
nclude mutation, amplification, deep deletion and multiple
lteration. Table 3 shows the alteration frequency of CDKs in
ifferent CRC data sources. This table reported the percentages of
ccurrence in selected case number, in different types of alteration.
n COAD (CPTAC-2, 2019) with a sample number of 105, the
requency of aleration observed were 17.14 %, 15.25 %, and 10.48 %
genes in the CRC. Grey bars along a vertical line represent the same
sample interrogated for genetic alteration. With two combined
studies containing 704 samples, 25 % of the queried genes were
altered (178). The mutations observed in CRC were deep deletion,
missenses and truncation mutations. Also, CRC may be thought to
frequently amplify CDKs. With respect to the 10 querried genes,
AURKA was frequently altered in CRC with 8% frequency of
alteration with amplification as the major alteration followed by
RB1 with 5% alterations (amplification, missense, deep deletion
and truncating mutation). However, among there genes, CDKN2A,
CDK1 and CDK4 were least altered with 1.9 %, 1.7 % and 1.4 %
frequencies of alteration respectively. In addition, the percentages
of alteration frequencies of five selected CRC samples (TCGA,
Firehose; TCGA, Nature; Pan Cancer; MSKCC and CPTAC-2 were
further investigated. The result shows that AURKA has the highest
alteration frequency across all five samples which sugegest that
the AURKA gene may be a good diagnostic biomarker for CRC
(Table 4).
3.7. Gene hotspot mutation for CDKs
The mutations of CDK-1 and CDK-4 were carried out using the
COSMIC database for CRC coupled with the cBioPortal database
for hotspot mutation in human cancers. These databases were
queried for CDK-1 and CDK-4 gene mutations. The pie charts
illustrate that the mutant types of CRC were primarily missense
and synonymous substitutions (Figs. 12A and 13 A). The CDK-1
and CDK-4 CRC data contained G > A and C > T mutations, each
ig. 4. Analysis of CDK-1 and CDK-4 expression in COAD and READ using UALCAN software based on nodal metastasis status. The expression of CDK-1 (A, B) and CDK-4 (C, D)
as significantly higher in COAD (A, C) and READ (B, D) tissues with lymph node metastasis than in normal tissues.*p < 0.01, ***p < 0.0001.or mutation, deep deletion and amplification respectively. Overall
he highest form of alteration was observed for mutation in all the
RC cases except in Colorectal (TCGA) data where 14.62 % for
mplification was observed as opposed 13.21 % for mutation.
Fig. 11 shows the percentages of alterations in CDK-4, CCNE1,
DKN2A, CCND2, RB1, CDK-1, BUB1, NCAPG, AURKA and KIF116
accounting for over 20 % of the genes coding strand (Figs. 12A
and 13 A). Using cBioPortal, 85,583 combined studies involving
82,346 patients from 277 studies of human cancers were
investigated. CDK mutations across these studies reported a
total of 169 and 302 mutations for CDK-1 and CDK-4
respectively. The mutation sites for CDK-1 was detected
A.O. Fadaka, N.R. Samantha Sibuyi, O.O. Bakare et al. Biotechnology Reports 29 (2021) e00602Fig. 5. Analysis of CDK-4 gene expression in CRC. The Box plot was derived from gene expression data in the Oncomine database. The expression of specific CDK-4 in normal
tissue vs cancer tissue.Fig. 6. Gene expression and prognostic value of CDK-1 in CRC (Oncomine and Prognoscan databases).between 0 and 297 amino acids of the PKinase domain whereas
the mutations site for CDK-4 was detected in the amino acids
range of 0–303. The PKinase domain represent the hotspot
domain for both genes (Figs. 12B and 13 B).7
3.8. Immune infiltration analysis
TIMER was used to investigate the molecular characterization
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ypes (COAD and READ). The output of each query generated
catter plots for each of the infiltrates in COAD and READ (Fig. 14).
n COAD, CDK-1 and CDK-4 clearly shows significant positive
orrelations with tumor purity while in READ, only CDK-4 was
ositively correlated with tumor purity. The expression levels of
ach gene were displayed against tumor purity (left). This is
ecause genes that are highly expressed in the microenvironment
re expected to have negative association with tumor purity. For
ach immune cell, the partial Spearman’s correlation was adjusted
y tumor purity (Fig. 14).
. Discussion
CDKs participate in the regulation of cell cycle progression and
ranscription, and aberrant expression of these genes is often
bserved in various human tumors. Dysregulation in cell cycle
rogression has been associated with bowel (small and large
ntestine) diseases particularly colon and rectum cancers repre-
enting one-fifth of all cancers globally [57]. Unlike normal cells,
immune infilterates in CRC. Most adenocarcinomas of the color-
ectum arise in a visible benign precursor lesion, the adenoma,
which is a monoclonal proliferation of dysplastic nonmalignant
epithelial cells [58]. Therefore, both adenoma and adenocarcinoma
of the colorectum were considered in this study.
The expression of CDKs was explored in 20 different cancer
subtypes with emphasis on different sections of the colorectum, using
different computational tools. Oncomine, TIMER and GEPIA web-
based tools wereusedtoevaluateandvalidatethemRNAexpression of
CDK-1 and CDK-4 in different cancer types (solid tumor and
hematological malignancies), different CRC sections as well as
clinico-pathological parameters of CRC in relation to normal tissues.
Relative to normal colorectum tissue, gene expression of CDK-1 and
CDK-4 were up-regulated in all major forms of cancerwith high mRNA
expressions observed in CRC. Xue et al. [59] revealed that the
expression of CDK-1 was exceptionally high in CRC in contrast with
normal tissues, and it predicts distance metastasis risk in CRC; CDK-1
can also alter the progression of CRC through phosphorylation of JAK1
to initiate the JAK/STAT3 signaling pathway. In addition, high
expression of CDK-1 reportedly stimulate the proliferation and
ig. 7. Correlation and Survival analysis of CDK-4 in CRC. (A) gene correlation between CDK-1 and CDK-4, Survival analysis of CDK-4 using (B) GEPIA database, (C) UCSC-Xena
atabase and (D) PrognoScan database.
ig. 8. Identification of known and predicted structural proteins crucial for CDK function. Interacting nodes are displayed in colored circles (STRING v11 plugin Cytoscape
.7.2). Predicted functional associations of CDK-1 (A) and CDK-4 (B) are shown based on experimental data, text-mining, co-expression, protein homology, and curated
atabase entries. PPI enrichment p-value: 3.75  1014.ancer cells grow uncontrollably without regulation by cell-cycle
ue to a loss of function of checkpoint integrity. This could be due
o CDK inhibitor inactivation leading to overexpression of either
yclin or CDKs. Therefore, these kinases are potential targets for
ancer theranostics. Using bioinformatics approaches, this study
nvestigated the roles of CDKs in relation to their expressions and8
migration of CRC while its inhibition restricted CRC proliferation
[60]. Furthermore, frequent CDK-1 expression was correlated with
therapeutic target, and the therapeutic resistance of BRAF mutant
human CRC can be suppressed by targeting CDK-1 [3]. Similarly, poor
prognosis was observed inpatients with high expression of CDK-4 (P <
0.001) [61]. Therefore, inhibition of these kinases may be useful in
A.O. Fadaka, N.R. Samantha Sibuyi, O.O. Bakare et al. Biotechnology Reports 29 (2021) e00602Fig. 9. Gene Ontology annotation of significantly enriched associated proteins with CDKs showing (A) cellular component, (B) biological process, (C) molecular function and
(D) biological pathway (FunRich software v3.1.3).cancer therapy and their expression patterns could become a novel
prognostic marker in CRC.
The protein expression level was also explored for reliable
prognostic values for CRC patients using in silico web-based
servers. Bioinformatics analyses have provided useful results based
on large experimentally validated data accesible in various9
databases. Gene expression prognostic signature for high-grade
serous ovarian cancer was investigated by resampling/cross-
validation method with Cox regression analysis followed by
Kaplan–Meier analysis and log-rank testing [62]. Similarly, He
et al. [63] probed the survival analysis of the expression level of
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ollowing this pattern, the prognostic values of CDK-1 and CDK-4
ere assessed using the comprehensive survival analysis platform
rognoScan-based Kaplan-Meier analyses. Expression of CDK-1
ositively correlated with poor OS and DFS in CRC patients while
he CDK-4 expression level of this study inversely correlated with
poor prognosis in DFS. Although CDK-1 and CDK-4 were positively
correlated, their prognostic values with respect to mRNA expres-
sion are contrasting. According to Li et al. [64] the overexpression
of CDK-1 in patients with CRC was associated with decreased OS.
Moreover, high mRNA expression of CDK-1 is linked to poor OS in
CRC, hepatocellular carcinoma and lung cancer [65–67]. This result
revealed that CDK-1 expression levels in CRC correlated with the
poor OS of patients with the disease. In addition, high expression of
CDK-1 is a prognostic factor for CRC.
Protein associations have been previously reported to be pivotal in
biological processes and cellular function in both prokaryotes and
eukaryotes including humans (normal and disease states) [68]. The
discovery of associated proteins with specific gene(s) of interest are
important to understand the mode of action of diseases such as cancer
to improve the development of therapeutic drugs and treatments-
strategies. Numerous experimental approaches have been deployed
for the identification of interacting genes but the processes are
demanding with limited outputs. However, bioinformatics approach
has been increasingly used to validate and predict elusive protein
partners. Therefore, this study identified twenty associated proteins
with CDK-1 and CDK-4 using STRING v11 plugin Cytoscape 3.7.2 since
proteins are constantly regulated and rarely function in isolation.
These genes are crucial to the roles and specific molecular networks of
CDK-1 and CDK-4 in diseases, most importantly CRC.
The ten associated proteins identified for CDK-1 include
Budding Uninhibited By Benzimidazoles 1 (BUB1), Non-SMC
Condensin I Complex Subunit G (NCAPG), Cyclin B1 (CCNB1),
Mitotic Arrest Deficient 2 Like 1 (MAD2L1), Aurora Kinase A
(AURKA), Cyclin A2 (CCNA2), Cyclin B2 (CCNB2), NDC80
Kinetochore Complex Component (NDC80), BUB1 Mitotic Check-
point Serine/Threonine Kinase B (BUB1B), and Kinesin Family
Member 11 (KIF11) with protein-protein interaction (PPI)
ig. 10. The alteration frequency of CDK-1 and CDK-4 along with the identified
rotein partners (A 21-gene) in 10 CRC studies. The studies include: COAD (CPTAC-2,
019, Colorectal (TCGA, PanCan), Colorectal (TCGA, pub), Colorectal (TCGA),
olorectal (Genentech), Colorectal (DFCI, 2016), CRC (MSK, 2018), Rectal (MSK,
019), COAD (Case CCC), and Colorectal (MSKCC) (cBioPortal).
ig. 11. Alteration frequency of gene signatures in CRC. The Oncoprint feature (cBioPortal database) was used to identify the CNA frequency of each gene in CDK within two
ombined studies (CRC, TCGA, and COAD, CPTAC-2).
able 3
lteration frequency of associated proteins signature with CDK-1 and CDK-4.
CRC Studies (Data source) N Freq. (%) Amp% (N) Mut.% (N) Deep Del.% (N) Mul. Alt. % (N)
COAD (CPTAC-2, 2019) 105 45.71 10.48 (11) 17.14 (18) 15.24 (16) 2.86 (3)
Colorectal (TCGA, PanCan) 526 30.01 10.65 (56) 12.17 (64) 5.32 (28) 1.90 (10)
Colorectal (TCGA, pub) 220 32.27 11.36 (25) 13.64 (30) 5.45 (12) 1.82 (4)
Colorectal (TCGA) 212 33.02 14.62 (31) 13.21 (28) 2.83 (6) 2.36 (5)
Colorectal (Genentech) 72 19.44 NA 19.44 (14) NA NA
Colorectal (DFCI, 2016) 619 17.77 NA 17.77 (110) NA NA
CRC (MSK, 2018) 1134 15.68 7.58 (86) 7.23 (18) 1.41 (16) 0.35 (4)
Rectal (MSK, 2019) 334 16.17 9.28 (14) 4.19 (14) 2.1 (7) 0.6 (2)
COAD (Case CCC) 29 3.45 NA 3.45 (1) NA NA
Colorectal (MSKCC) 138 1.45 NA 1.45 (2) NA NAbbreviations: N: study number (Cases); Freq: Frequency in Percentage; Mut %: Mutation; Deep Del%: Deep Deletion; Mul. Alt: Multiple Alterations; COAD (CPTAC-2, 2019):
olon Cancer (CPTAC-2 Prospective, Cell 2019); Colorectal (TCGA, PanCan): Colorectal Adenocarcinoma (TCGA PanCancer Atlas); Colorectal (TCGA, pub): Colorectal
denocarcinoma (TCGA Firehose Legacy); Colorectal (TCGA): Colorectal Adenocarcinoma (TCGA, Nature 2012); Colorectal (Genentech): Colorectal Adenocarcinoma
Genentech, Nature 2012); Colorectal (DFCI, 2016): Colorectal Adenocarcinoma (DFCI, Cell Reports 2016); CRC (MSK, 2018): Metastatic Colorectal Cancer (MSKCC, Cancer Cell
018); Rectal (MSK, 2019): Rectal Cancer (MSK Nature Medicine 2019); COAD (Case CCC): Colon Adenocarcinoma (CaseCCC, PNAS 2015); Colorectal (MSKCC): Colon
denocarcinoma Triplets (MSKCC, Genome Biol 2014); and NA: Not Applicable.
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Genetic alteration summary of genes of interest in five CRC samples.
Data CDK-1 CDK-4 CCNE1 CDKN2A RB1 BUB1 NCAPG AURKA KIF11 CCND2
CRC, TCGA, Firehose 0.5 % 1.4 % 2..7 % 1.8 % 5% 3% 3% 8% 4% 2.7 %
CRC, TCGA, Nature 0.5 % 0.9 % 1.9 % 2.4 % 3% 2.8 % 3% 10 % 4% 1.9 %
CRC, Pan Cancer 1.9 % 1.1 % 1.5 % 2.1 % 5% 3% 4% 7% 2.9 % 3%
MSKCC 0% 0.7 % 1% 2.9 % 3% 0% 0% 4% 0% 1%
CPTAC-2 1.9 % 2.9 % 4% 1.9 % 7% 6% 6% 8% 11 % 2.9 %
Fig. 12. CDK-1 mutation in CRC patients. (A) The percentages of mutation types of CDK-1 in CRC were revealed in a pie chart generated from the COSMIC database. (B)
cBioPortal was used to analyze the genetic alteration frequency of CDK-1 mutations in CRC.
Fig. 13. CDK-4 mutation in CRC patients. (A) The percentages of mutation types of CDK-4 in CRC were revealed in a pie chart generated from the COSMIC database. (B)
cBioPortal was used to analyze the genetic alteration frequency of CDK-4 mutations in CRC.enrichment p-value of 3.75  1014, average node degree of 9.27
and average local clustering coefficient of 0.943.
With an enrichment p-value of 4.44  1016, average node degree
of 10 and average local clustering coefficient of 1.0, CDK-4 was
equally associated with ten genes namely; Cyclin D3 (CCND3),11Cyclin-Dependent Kinase Inhibitor 2B (CDKN2B), Cyclin-Depen-
dent Kinase Inhibitor 1A (CDKN1A), Cyclin-Dependent Kinase
Inhibitor 2A (CDKN2A), Cyclin D2 (CCND2), Cyclin D1 (CCND1), RB
Transcriptional Corepressor 1 (RB1), Cyclin-Dependent Kinase
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n different cancers [68–71]. Mizuarai et al. [69] reported the in vivo
nd in vitro expression of CCND1/CDKN2A status in 30 cancer cell
ines composed of 16 RB1-positive and 14 RB1-negative cancers. The
tudy identified a panel of genes which could predict RB1 status in
oth cultured cancer cell lines and clinical tumor samples. AURKA
enes was studied to provide cancer therapeutic interventions due
o their significant expression in cancer patient samples [70].
imilarly, Korobeynikov et al. [71] suggested that the dual targeting
f AURKA and PAK1 may be a promising therapeutic strategy for
ancer treatment from a combinatory study of alisertib and
RAX1036. Another study by Ding et al. [72] shows that MAD2L1
ay be a novel oncogene in an in vitro 20 clinical CRC samples. Since
revious studies have predicted the association of these genes as
romising targets in cancer therapy [73,74], CDKs together with
heir protein partners could serve as a confirmation of the strength
f the methodology used in this study.
The discovery of pathways and specific processes that are
ignificant with factors regulating activities to genes of interest is
mportant in cancer research. FunRich software was used to
valuate the enrichment of the protein partners in BP, MF and CC.
hese genes were involved in: a) cell communication and signal
ransduction in BP, b) kinase binding and kinase regulator activity
n MF, c) cyclin-dependent protein kinase holoenzyme complex
nd nucleoplasm in CC and d) cell cycle, mitotic and FOXM1
the bar chart, the alterations include mutation, amplification, deep
deletion and multiple alterations. The mutation data and copy
number alterations were also represented. The ratio of alteration
ranged between 1.45 and 45.71 % with the dominance hierarchy as
Colon Cancer (CPTAC-2 Prospective, Cell 2019), Colorectal Adeno-
carcinoma (TCGA, Nature 2012) and Colorectal Adenocarcinoma
(TCGA Firehose Legacy). Furthermore, alterations in the associated
genes (CDK-1, CDK-4, CCNE1, CDKN2A, RBI, NCAPG, AURKA, and
CCND2) were determined in five CRC studies (CRC, TCGA, Firehose,
CRC, TCGA, Nature, CRC, Pan-Cancer, MSKCC and CPTAC-2). The
percentages of alterations in these genes ranged from 0 to 11% for
individual genes. AURKA and RB1 genes were amplified predomi-
nantly in the combined studies, suggesting that their expression
could be significant to CRC prognosis. Since these genes are
positively correlated with CDK genes, their prognostic values
deserve to be assessed for theranostic purposes.
The alterations frequencies and hotspot mutations of CDK-1 and
CDK-4 were analyzed with COSMIC and cBioPortal databases. The
results revealed that the types of mutations of CDK-1 and CDK-4 in
the CRC data were missense mutations among others. Further-
more, the alteration frequency of these genes in CRC is notably low.
CDK genes were altered in 2,537 of the queried samples (3%), with a
somatic mutation frequency of 0.2 % for both CDK-1 and CDK-4. For
CDK-1, 169 mutations including 130 missenses, 32 truncating, 4 in-
frame insertions, and 3 others with E163* hotspot were observed.
ig. 14. Correlation of CDK-1 and CDK4 expression with immune purity and fraction of immune cells in COAD (colon adenocarcinoma) and READ (rectum adenocarcinoma).
he scatterplots showed the purity-corrected partial Spearman's correlation and statistical significance. (A) CDK-1 expression is significantly positively related to tumor
urity as well as B cells, CD8 + T cells, macrophages, neutrophils, and dendritic cells and has significant negative correlations with infiltrating level of CD4 + T cells in COAD (n =
57). In contrast, a negative correlation was observed in tumor purity as well as CD4 + T and macrophages in READ. (B) CDK-4 expression has significant correlations with
umor purity and infiltrating levels of macrophages in COAD and dendritic cells in READ (n = 166).ranscription factor network in BP. These processes can be further
robed for their involvement in CRC in order to tailor specific
trategies for CRC therapeutics.
In a combined study of 3,953 samples, the associated genes
ere altered in 21 % (817) of queried samples reporting 46 % altered
ases as the alteration frequency (cancer types summary). From1
In a total of 302 mutations for CDK-4, including 264 missenses, 17
truncating, 7 in-frame insertions, and 14 others its hotspot was
identified as a R24A/C/H/L hotspot. The clinical implications of
these mutation hotspots are likely to be oncogenic with gain of
function as the biological effect. CDK-1 and CDK-4 are significant
kinases in M-phase andG1 stages of cell-cycle respectively. Unlike2
A.O. Fadaka, N.R. Samantha Sibuyi, O.O. Bakare et al. Biotechnology Reports 29 (2021) e00602the aberrant expression of CDK-1 in stage-2 colon and rectum
adenocarcinoma being associated with a higher risk of metastasis
[75], mutations in the catalytic subunit of CDK-4 gene has also been
reported to be common and its abnormal expression has been
uncovered in over 90 % of all bowel cancers [76]. The identified
hotspots for these kinases may be a promising drug target.
During tumor development and progression, cancer and
immune cells interact by multiple genes and pathways. Therefore,
it is worthy to explore the correlation between gene expression
and immune infiltration level. Tumor purity plays an important
role in understanding the pathogenic mechanism of tumors [77].
This is a crucial characteristic that cannot be ignored in cancer
genomics or epigenomics data analysis [78]. It is noteworthy that
the increase in tumor purity was inversely correlated with the
expression of CDK-1 in READ. Specifically, the immune infiltration
analysis may have resulted from an increase in the numbers of
infiltrating B cells, CD8+cells, neutrophils, and dendritic cells.
Conversely, an increase in tumor purity was positively correlated
with the expression of CDK-1 in COAD due to CD4+cells and CDK-4
in COAD and READ resulting from a fraction of immune cells.
5. Conclusion
Dysregulation of kinase genes is commonly encountered in bowel
cancers. In this study, CDK-1 and CDK-4 genes were overexpressed in
all the CRC subtypes with respect to normal tissues and the expression
of CDK-1 was associated with poor prognosis as opposed to CDK-4.
Based on the associated proteins, RB1 and AURKA were positively
correlated and showed significant relationships with CDKs and their
expressions were significantly altered in CRC. The most frequent
alteration was found to be a mutation with hotspots E163* and R24A
located on the Pkinase domain for both CDK-1 and CDK-4 respectively.
In addition, one of the crucial findings of the current study was the
identification of a positive correlation between CDK-1 and increased
numbers of infiltrating B cells, CD8+ cells, neutrophils and dendritic
cells and a contrasting correlation between CDK-4 and the immune
infiltrates in both CRC subtypes. This is a potential novel feature of CRC
in the context of the immune response, driven by CDK-1 and CDK-4. In
concluson, the results of this study justified exploring CDKs as
prognostic markers as well as immunotherapeutic target for CRC as
well as other cancers. The role of these genes in CRC and the potential
molecular mechanisms deserve further molecular investigation.
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